State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization. Volume 2, Biopharmaceutical characterization /
State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization. Volume 2, Biopharmaceutical characterization /
Biopharmaceutical characterization
edited by John E. Schiel, Darryl L. Davis, Oleg V. Borisov.
- New York : Oxford University Press, 2016.
- 448 pages : illustrations ; 23 cm.
- ACS symposium series State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization ; volume 2 ACS symposium series ; 1201 .
- ACS symposium series ; 1201 State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization ; v. 2 .
Includes bibliographical references and index.
1.Determination of the NIST mAB primary structure. Trina Formolo ... [et al] -- 2.Sequence varianst and sequence variant analysis in biotherapeutic protins. Oleg V. Borisov ... [et al] -- 3.Structural elucidation of post-translational modifications in monoclonal antibodies. Wenzhou Li ... [et al] -- 4.Orthogonal technologies for NIST mAB N-Glycan structure elucidation and quantitation. Justin M. Prien ... [et al] -- 5.Separation methods and orthogonal techniques. David A. Michels ... [et al] -- 6.Biophysical techniques for characterizing the higher order structure and interactions of monoclonal antibodies. Yatin Gokarn ... [et al] -- 7.Developability assessment of a proposed INST monoclonal antibody.Dorina Saro ... [et al] -- 8.Protein particles (0.01 æm, 0.01 æm. Dean C. Ripple and Linda O. Narhi -- 9.Analytical methods for the measurement of host cell proteins and other process-related impurities. Kesh Prakahs and Weibin Chen.
This volume looks at the characterisation of monoclonal antibodies (mAbs), focusing both on general aspects, techniques and regulatory concerns common to any recombinant protein as well as specific analytical results. It therefore serves as both a foundational body of NISTmAb product knowledge as well as an evaluation of its suitability as an industry-appropriate reference material.
9780841230293 (hbk.) : £115.00 0841230293
Immunoglobulins--Therapeutic use
Monoclonal antibodies.
Pharmaceutical biotechnology.
Biopharmaceutics.
Monoclonal antibodies.
Health and Wellbeing.
Biochemistry
Pharmacology
Organic chemistry
Pharmaceutical chemistry & technology
QR186.85 / .S73 2016
Includes bibliographical references and index.
1.Determination of the NIST mAB primary structure. Trina Formolo ... [et al] -- 2.Sequence varianst and sequence variant analysis in biotherapeutic protins. Oleg V. Borisov ... [et al] -- 3.Structural elucidation of post-translational modifications in monoclonal antibodies. Wenzhou Li ... [et al] -- 4.Orthogonal technologies for NIST mAB N-Glycan structure elucidation and quantitation. Justin M. Prien ... [et al] -- 5.Separation methods and orthogonal techniques. David A. Michels ... [et al] -- 6.Biophysical techniques for characterizing the higher order structure and interactions of monoclonal antibodies. Yatin Gokarn ... [et al] -- 7.Developability assessment of a proposed INST monoclonal antibody.Dorina Saro ... [et al] -- 8.Protein particles (0.01 æm, 0.01 æm. Dean C. Ripple and Linda O. Narhi -- 9.Analytical methods for the measurement of host cell proteins and other process-related impurities. Kesh Prakahs and Weibin Chen.
This volume looks at the characterisation of monoclonal antibodies (mAbs), focusing both on general aspects, techniques and regulatory concerns common to any recombinant protein as well as specific analytical results. It therefore serves as both a foundational body of NISTmAb product knowledge as well as an evaluation of its suitability as an industry-appropriate reference material.
9780841230293 (hbk.) : £115.00 0841230293
Immunoglobulins--Therapeutic use
Monoclonal antibodies.
Pharmaceutical biotechnology.
Biopharmaceutics.
Monoclonal antibodies.
Health and Wellbeing.
Biochemistry
Pharmacology
Organic chemistry
Pharmaceutical chemistry & technology
QR186.85 / .S73 2016